Clinical applications of Silybum marianum in oncology

被引:51
作者
Greenlee, Heather
Abascal, Kathy
Yarnell, Eric
Ladas, Elena
机构
[1] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA
[2] Bastyr Univ, Sch Naturopath Med, Dept Bot Med, Kenmore, WA USA
[3] Columbia Univ, Div Pediat Oncol, New York, NY USA
关键词
milk thistle; Silybum marianum; clinical applications; oncology;
D O I
10.1177/1534735407301727
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Milk thistle (Silybum marianum) is an herb that is increasingly used in oncology research and treatment settings. Historically, it has been used to treat liver and biliary disorders and has been used in detoxification and cleansing protocols. However, milk thistle is increasingly being investigated for its use in adult and pediatric populations for oncology indications. Possible indications during cancer treatment include cleansing and detoxification after chemotherapy, preventing hepatotoxicity during chemotherapy, treating hepatotoxicity after chemotherapy, and potentiating chemotherapy and radiation therapy as an adjunctive treatment. Milk thistle may also have applications in ameliorating longterm hepatic and cardiovascular effects of cancer treatment. Preliminary studies are investigating its use as a chemopreventive agent and possibly to treat cancer directly. Much of milk thistle's current clinical use grows out of historical uses but is informed by an increasing number of clinical trials and animal studies. This article provides an overview of the current clinical applications of milk thistle in the oncology setting, including guidelines on commonly used forms and doses.
引用
收藏
页码:158 / 165
页数:8
相关论文
共 74 条
[1]  
Abascal K., 2003, Altern. Complement. Ther., V9, P170, DOI [10.1089/107628003322256878, DOI 10.1089/107628003322256878]
[2]  
Adverse Drug React Advisory Comm, 1999, MED J AUSTRALIA, V170, P218
[3]   Photochemoprevention by botanical antioxidants [J].
Afaq, F ;
Mukhtar, H .
SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 2002, 15 (05) :297-306
[4]   Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease [J].
Allain, H ;
Schück, S ;
Lebreton, S ;
Strenge-Hesse, A ;
Braun, W ;
Gandon, JM ;
Brissot, P .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) :181-185
[5]  
[Anonymous], 2006, TXB NATURAL MED
[6]  
[Anonymous], KINGS AM DISPENSATOR
[7]  
[Anonymous], 2000, GREEN PHARM HERBAL H
[8]  
[Anonymous], 1998, COMPLETE GERMAN COMM
[9]   Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion [J].
Assaf, C. ;
Bagot, M. ;
Dummer, R. ;
Duvic, M. ;
Gniadecki, R. ;
Knobler, R. ;
Ranki, A. ;
Schwandt, P. ;
Whittaker, S. .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (02) :261-266
[10]  
Berkson BM, 1999, MED KLIN, V94, P84, DOI 10.1007/BF03042201